Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

pharmathen s.a. - valaciclovir (valaciclovir hydrochloride) - tablets film-coated - 500mg

Ireland - English - HPRA (Health Products Regulatory Authority)

pharmathen s.a. - atorvastatin - film coated tablet - 40 milligram - hmg coa reductase inhibitors

Ireland - English - HPRA (Health Products Regulatory Authority)

pharmathen s.a. - atorvastatin calcium - film coated tablet - 20 milligram - hmg coa reductase inhibitors

Ireland - English - HPRA (Health Products Regulatory Authority)

pharmathen s.a. - atorvastatin calcium - film coated tablet - 80 milligram - hmg coa reductase inhibitors

Ireland - English - HPRA (Health Products Regulatory Authority)

pharmathen s.a. - atorvastatin calcium - film coated tablet - 10 milligram - hmg coa reductase inhibitors

Ireland - English - HPRA (Health Products Regulatory Authority)

pharmathen s.a. - topiramate - film coated tablet - 100 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

pharmathen s.a. - topiramate - film coated tablet - 25 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

pharmathen s.a. - topiramate - film coated tablet - 50 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

pharmathen s.a. - topiramate - film coated tablet - 200 milligram

European Union - English - EMA (European Medicines Agency)

pharmathen s.a. - clopidogrel (as besilate) - peripheral vascular diseases; stroke; myocardial infarction - antithrombotic agents - prevention of atherothrombotic eventsclopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome:non-st-segment-elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa);st-segment-elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.prevention of atherothrombotic and thromboembolic events in atrial fibrillationin adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin-k antagonists and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke.